These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 25803091)
1. Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. Daly AK Drug Metab Pers Ther; 2015 Sep; 30(3):165-74. PubMed ID: 25803091 [TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacogenetics and potential application in personalized medicine. Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects. Lu S; Nand RA; Yang JS; Chen G; Gross AS Eur J Clin Pharmacol; 2018 Mar; 74(3):285-296. PubMed ID: 29181698 [TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population. Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143 [TBL] [Abstract][Full Text] [Related]
5. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics. Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A; OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544 [TBL] [Abstract][Full Text] [Related]
6. Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population. Céspedes-Garro C; Rodrigues-Soares F; Jiménez-Arce G; Naranjo MG; Tarazona-Santos E; Fariñas H; Barrantes R; Llerena A; Rev Biol Trop; 2016 Sep; 64(3):1067-76. PubMed ID: 29461783 [TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of common SNP affecting drug metabolizing enzymes: comparison of allele frequencies between European and Malaysian/Singaporean. Bakar NS Drug Metab Pers Ther; 2021 Mar; 36(3):173-181. PubMed ID: 34412170 [TBL] [Abstract][Full Text] [Related]
8. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population. Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Bahar MA; Setiawan D; Hak E; Wilffert B Pharmacogenomics; 2017 May; 18(7):701-739. PubMed ID: 28480783 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of drug-metabolizing enzymes in Italian populations. Serpe L; Canaparo R; Scordo MG; Spina E Drug Metab Pers Ther; 2015 Jun; 30(2):107-20. PubMed ID: 25527811 [TBL] [Abstract][Full Text] [Related]
11. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine? de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029 [TBL] [Abstract][Full Text] [Related]
12. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review. Dorji PW; Tshering G; Na-Bangchang K J Clin Pharm Ther; 2019 Aug; 44(4):508-524. PubMed ID: 30980418 [TBL] [Abstract][Full Text] [Related]
13. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905 [TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms. Chaudhry SR; Muhammad S; Eidens M; Klemm M; Khan D; Efferth T; Weisshaar MP Curr Drug Metab; 2014; 15(7):711-8. PubMed ID: 25429673 [TBL] [Abstract][Full Text] [Related]
16. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309 [TBL] [Abstract][Full Text] [Related]
17. Allelic expression of phase II metabolizing enzymes and relationship to irinotecan toxicity. Tadje M Oncol Nurs Forum; 2014 Jul; 41(4):443-4. PubMed ID: 24969255 [TBL] [Abstract][Full Text] [Related]
18. CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study. Saldaña-Cruz AM; León-Moreno LC; Sánchez-Corona J; Santiago DA; Mendoza-Carrera F; Castro-Martínez XH; García-Zapién AG; Morán-Moguel MC; Flores-Martínez SE Genet Test Mol Biomarkers; 2016 Nov; 20(11):702-709. PubMed ID: 27617498 [TBL] [Abstract][Full Text] [Related]
19. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Matimba A; Del-Favero J; Van Broeckhoven C; Masimirembwa C Hum Genomics; 2009 Jan; 3(2):169-90. PubMed ID: 19164093 [TBL] [Abstract][Full Text] [Related]
20. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population. Skadrić I; Stojković O Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]